These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38910253)

  • 21. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Langerhans cell histiocytosis: retrospective analysis of 217 cases in a single center.
    Yağci B; Varan A; Cağlar M; Söylemezoğlu F; Sungur A; Orhan D; Yalçin B; Akyüz C; Kutluk T; Büyükpamukçu M
    Pediatr Hematol Oncol; 2008 Jun; 25(5):399-408. PubMed ID: 18569842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland.
    Raciborska A; Bilska K; Węcławek-Tompol J; Gryniewicz-Kwiatkowska O; Hnatko-Kołacz M; Stefanowicz J; Pieczonka A; Jankowska K; Pierelejewski F; Ociepa T; Sobol-Milejska G; Muszyńska-Rosłan K; Michoń O; Badowska W; Radwańska M; Drabko K
    BMC Cancer; 2020 Sep; 20(1):874. PubMed ID: 32917181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
    Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
    Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
    Barkaoui MA; Queheille E; Aladjidi N; Plat G; Jeziorski E; Moshous D; Lambilliotte A; Kebaili K; Pacquement H; Leverger G; Mansuy L; Entz-Werlé N; Bodet D; Schneider P; Pagnier A; Lutun A; Gillibert-Yvert M; Millot F; Toutain F; Reguerre Y; Thomas C; Tazi A; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2020 Dec; 191(5):825-834. PubMed ID: 32700439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
    Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
    Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
    Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
    Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis.
    Monsereenusorn C; Suwannaying K; Buaboonnam J; Sathitsamitphong L; Techavichit P; Pakakasama S; Chainansamit SO; Anurathapan U; Komvilaisak P; Traivaree C; Sanpakit K; Charoenkwan P; Seksarn P
    Asian Pac J Cancer Prev; 2024 May; 25(5):1831-1839. PubMed ID: 38809656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis.
    Kudo K; Maeda M; Suzuki N; Kanegane H; Ohga S; Ishii E; Shioda Y; Imamura T; Imashuku S; Tsunematsu Y; Endo M; Shimada A; Koga Y; Hashii Y; Noguchi M; Inoue M; Tabuchi K; Morimoto A;
    Int J Hematol; 2020 Jan; 111(1):137-148. PubMed ID: 31758416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of langerhans cell histiocytosis in children].
    Bilić E; Bojanić K; Pavlović M; Konja J; Femenić R; Dapić T; Antabak A; Anticević D; Murat-Susić S; Husar K; Potocki K; Rajić L
    Lijec Vjesn; 2011; 133(11-12):376-84. PubMed ID: 22329293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 5-Year EFS of Multisystem LCH With Risk-Organ Involvement Is Suboptimal: A Single-center Experience From India.
    Totadri S; Bansal D; Trehan A; Srinivasan R; Varma N; Kakkar N; Saxena AK; Bhatia P
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e1-5. PubMed ID: 26274033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement.
    Miao HL; Zhao AL; Duan MH; Zhou DB; Cao XX; Li J
    BMC Cancer; 2020 Sep; 20(1):911. PubMed ID: 32967635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
    Abraham A; Alsultan A; Jeng M; Rodriguez-Galindo C; Campbell PK
    Pediatr Blood Cancer; 2013 Jun; 60(6):E19-22. PubMed ID: 23255383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
    Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
    Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
    Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
    Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.